Suppl. Table 1. The physicochemical properties of the PLGA nanocerriers

Formulation	Size (nm)	PDI	Zeta potential (mV)
NPs-RFL	293.90±6.06	0.14±0.04	-25.74±2.38
NPs-RFL-Ab	305.33±36.42	0.22±0.16	-17.91±5.56

Each value represents the mean±S.E.M. (*n*=3).

PDI: polydispersity index.



Suppl. Figure 1. The association of rhodamine 800-loaded isotype antibody-conjugated nanoparticles with the human neutrophils examined by flow cytometry



Suppl. Figure 2. Hand-held digital microscopy shows close-up pictures from Day 0 to Day 5



Supp. Figure 3. The neutrophil-targeted PLGA nanoparticles ameliorate IMQ-induced psoriatic skin inflammation by subcutaneous administration



Supp. Figure 4. The monovalent NIMP-R14-conjugated roflumilast-loaded nanoparticles inhibit neutrophil-related cytokines and chemokines in IMQ-induced psoriasis-like skin by subcutaneous administration



Suppl. Figure 5. Monovalent NIMP-R14-conjugated roflumilast-loaded nanoparticles are biocompatible and safe for repeated subcutaneous dosing